Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.

@article{Ding2009TargetingII,
  title={Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.},
  author={Changhai H Ding and Flavia Cicuttini and Jun Li and Graeme Jones},
  journal={Expert opinion on investigational drugs},
  year={2009},
  volume={18 10},
  pages={1457-66}
}
BACKGROUND IL-6, a glycoprotein composed of 212 amino acids in human, has a wide range of biological activity, including regulation of immune response, support of hematopoiesis, generation of acute-phase reactions and induction of inflammation and oncogenesis. Several approaches including inhibition of IL-6 production, blockage of IL-6 binding to IL-6 receptor, blockage of IL-6/IL-6R complex binding to gp 130 and blockage of the intracytoplasmic signal through gp 130 can be used to block IL-6… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation.

Expert opinion on investigational drugs • 2012
View 4 Excerpts
Highly Influenced

Morroniside on anti-inflammation activities in rats following acute myocardial infarction

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology • 2018
View 1 Excerpt

Renal ischemia-reperfusion injury attenuated by splenic ischemic preconditioning.

European review for medical and pharmacological sciences • 2018

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Safety of tocilizumab in patients with rheumatoid arthritis: an interim analysis of long-term extension trials with a mean treatment duration of 1.5 years

RF van Vollenhoven, J Smolen, HPT Tony
Arthritis Rheum • 2008
View 3 Excerpts
Highly Influenced

Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.

Bulletin of the NYU hospital for joint diseases • 2007
View 4 Excerpts
Highly Influenced

Long-term treatment of systemic onset juvenile idiopathic arthritis (SO-JIA) with humanized anti-IL-6 receptor monoclonal antibody, tocilizumab (Actemra (R))

S Yokota, T Miyamae, R Kurosawa
Arthritis Rheum • 2005
View 6 Excerpts
Highly Influenced

26 1 1 Se pt em be r 20 15 Targeting IL-6 in the treatment of inflammatory and autoimmune diseases 1466 Expert Opin

P Gamero, E Mareau, L Thompson, 0 6WoodworthT.Theanti-IL6receptorDownloadedbyat
Investig. Drugs • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…